HK1248680A1 - 包含吡嗪并[2，3-b][1，4]恶嗪-3-酮或相关环系的抗菌剂 - Google Patents

包含吡嗪并[2，3-b][1，4]恶嗪-3-酮或相关环系的抗菌剂 Download PDF

Info

Publication number
HK1248680A1
HK1248680A1 HK18108126.0A HK18108126A HK1248680A1 HK 1248680 A1 HK1248680 A1 HK 1248680A1 HK 18108126 A HK18108126 A HK 18108126A HK 1248680 A1 HK1248680 A1 HK 1248680A1
Authority
HK
Hong Kong
Prior art keywords
pyrazino
oxazin
ring system
antibacterial agents
related ring
Prior art date
Application number
HK18108126.0A
Other languages
English (en)
Chinese (zh)
Inventor
Haifeng Cui
Alan Hennessy
Qi Jin
Timothy James Miles
Stephen Frederick Moss
Neil David Pearson
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of HK1248680A1 publication Critical patent/HK1248680A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
HK18108126.0A 2015-08-16 2016-08-15 包含吡嗪并[2，3-b][1，4]恶嗪-3-酮或相关环系的抗菌剂 HK1248680A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562205732P 2015-08-16 2015-08-16
US62/205,732 2015-08-16
US201662308928P 2016-03-16 2016-03-16
US62/308,928 2016-03-16
PCT/IB2016/054890 WO2017029602A2 (en) 2015-08-16 2016-08-15 Compounds for use in antibacterial applications

Publications (1)

Publication Number Publication Date
HK1248680A1 true HK1248680A1 (zh) 2018-10-19

Family

ID=57218948

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18108126.0A HK1248680A1 (zh) 2015-08-16 2016-08-15 包含吡嗪并[2，3-b][1，4]恶嗪-3-酮或相关环系的抗菌剂

Country Status (22)

Country Link
US (2) US10364254B2 (https=)
EP (1) EP3334739A2 (https=)
JP (1) JP6757402B2 (https=)
KR (1) KR20180038046A (https=)
CN (1) CN108137616B (https=)
AU (2) AU2016307969C1 (https=)
CA (1) CA2995715A1 (https=)
CL (1) CL2018000403A1 (https=)
CO (1) CO2018002204A2 (https=)
CR (1) CR20180111A (https=)
DO (1) DOP2018000049A (https=)
EA (1) EA033314B1 (https=)
HK (1) HK1248680A1 (https=)
IL (1) IL257265B (https=)
MA (1) MA42621A (https=)
MX (1) MX2018002033A (https=)
PE (1) PE20181143A1 (https=)
PH (1) PH12018500358A1 (https=)
TW (1) TW201722965A (https=)
UY (1) UY36851A (https=)
WO (1) WO2017029602A2 (https=)
ZA (1) ZA201800722B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722965A (zh) * 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 用於抗菌應用之化合物
WO2019180634A1 (en) 2018-03-23 2019-09-26 Glaxosmithkline Intellectual Property Development Limited Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes
TW202116782A (zh) 2019-07-16 2021-05-01 瑞士商愛杜西亞製藥有限公司 喹啉酮衍生物
CN111269247B (zh) * 2020-03-04 2020-11-24 河南科技大学第一附属医院 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds
WO2025132870A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Intellectual Property (No.4) Limited Chemical compounds and uses thereof

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (https=) * 1969-10-13 1971-09-23 Eisai Co Ltd
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH0733379B2 (ja) * 1986-06-27 1995-04-12 エーザイ株式会社 光学活性α−トコフエロ−ルの製造方法
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
EP1306038B1 (en) 2000-07-21 2005-12-21 Ljudmila Petrovna Maljuk Plate for a stand-up meal
EP1305308B1 (en) 2000-07-26 2006-12-20 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
EP1345903A1 (en) 2000-12-21 2003-09-24 Ciba SC Holding AG Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
EP1470131A2 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US7312212B2 (en) 2002-01-29 2007-12-25 Glaxo Group Limited Aminopiperidine derivatives
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
TW200406413A (en) * 2002-06-26 2004-05-01 Glaxo Group Ltd Compounds
AR040336A1 (es) * 2002-06-26 2005-03-30 Glaxo Group Ltd Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
WO2004002990A2 (en) 2002-06-27 2004-01-08 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
EP1551829B1 (de) 2002-10-10 2010-04-07 Morphochem Aktiengesellschaft Für Kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
US7232832B2 (en) 2002-11-05 2007-06-19 Smithkline Beecham Corporation Antibacterial agents
EP1560488B1 (en) 2002-11-05 2010-09-01 Glaxo Group Limited Antibacterial agents
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
TW200507841A (en) * 2003-03-27 2005-03-01 Glaxo Group Ltd Antibacterial agents
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
MXPA06006738A (es) 2003-12-19 2006-08-31 Univ North Carolina Metodos para fabricar micro- y nano-estructuras aisladas utilizando litografia suave o de impresion.
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
WO2006002047A2 (en) 2004-06-15 2006-01-05 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
JP2008505920A (ja) 2004-07-08 2008-02-28 グラクソ　グループ　リミテッド 抗菌剤
US20080194547A1 (en) 2004-07-09 2008-08-14 Glaxo Group Limited Antibacterial Agents
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US20070270417A1 (en) 2004-07-22 2007-11-22 Glaxo Group Limited Antibacterial Agents
WO2006017468A2 (en) 2004-08-02 2006-02-16 Glaxo Group Limited Antibacterial agents
JP2008509222A (ja) 2004-08-09 2008-03-27 グラクソ グループ リミテッド 抗菌剤
DE102004041163A1 (de) * 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP4887297B2 (ja) 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
DE602005021133D1 (de) 2004-10-05 2010-06-17 Actelion Pharmaceuticals Ltd Neue piperidin-antibiotika
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
JP2008528598A (ja) 2005-01-25 2008-07-31 グラクソ グループ リミテッド 抗菌剤
MX2007014507A (es) 2005-05-24 2008-02-07 Astrazeneca Ab Aminopiperidin quinolinas y sus analogos azaisostericos con actividad antibacteriana.
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
EP1900732A4 (en) 2005-06-24 2009-11-18 Toyama Chemical Co Ltd NEW NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
EP2537657A3 (en) 2005-08-09 2016-05-04 The University of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
WO2007081876A2 (en) 2006-01-04 2007-07-19 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
ES2353829T3 (es) * 2006-02-15 2011-03-07 Actelion Pharmaceuticals Ltd. Derivados antibioticos de etanol o de 1,2-etanodiolciclohexilo.
AU2007268749B2 (en) 2006-05-26 2012-07-26 Taisho Pharmaceutical Co., Ltd. Novel heterocyclic compound or salt thereof and intermediate thereof
EP1992628A1 (en) * 2007-05-18 2008-11-19 Glaxo Group Limited Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones
WO2008013952A2 (en) 2006-07-27 2008-01-31 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
CL2007003693A1 (es) * 2006-12-22 2008-06-27 Actelion Pharmaceuticals Ltd Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
GB0707704D0 (en) * 2007-04-20 2007-05-30 Glaxo Group Ltd Compounds
WO2009024342A2 (en) * 2007-08-23 2009-02-26 Syngenta Participations Ag Novel microbiocides
EP2207670B1 (en) 2007-10-12 2019-05-22 Liquidia Technologies, Inc. Method for producing particles and patterned films
JP5620636B2 (ja) 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
DK2344495T3 (en) * 2008-10-07 2015-02-02 Actelion Pharmaceuticals Ltd TRICYCLIC OXAZOLIDINON ANTIBIOTIC COMPOUNDS
WO2010045987A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quin0lin-2-0nes as antibacterials
TW201022279A (en) * 2008-11-14 2010-06-16 Astrazeneca Ab Chemical compounds
KR101690643B1 (ko) 2008-12-05 2016-12-28 리퀴디아 테크놀로지스 인코포레이티드 패턴 재료 제조 방법
AU2009325902B2 (en) * 2008-12-12 2015-01-29 Idorsia Pharmaceuticals Ltd 5-amino-2-(1-hydroxy-ethyl)-tetrahydropyran derivatives
JP5656996B2 (ja) 2009-07-13 2015-01-21 ザ ユニバーシティ オブ ノース キャロライナ アット チャペル ヒル 工学的に作製されたエアロゾル粒子、およびそれに関連した方法
TW201209056A (en) * 2010-05-25 2012-03-01 Taisho Pharmaceutical Co Ltd Novel heterocyclic compound or salt thereof
CA2840060A1 (en) * 2011-06-27 2013-01-03 Kyorin Pharmaceutical Co., Ltd. Bridged bicyclic compounds for the treatment of bacterial infections
TW201326180A (zh) * 2011-11-30 2013-07-01 Actelion Pharmaceuticals Ltd ３，７－二取代八氫－２Ｈ－吡啶并［４，３－ｅ］［１，３］□嗪－２－酮抗生素
KR20150143720A (ko) 2013-04-16 2015-12-23 액테리온 파마슈티칼 리미티드 항균성 이방향족 유도체
TW201722965A (zh) * 2015-08-16 2017-07-01 葛蘭素史密斯克藍智慧財產發展有限公司 用於抗菌應用之化合物

Also Published As

Publication number Publication date
PH12018500358A1 (en) 2018-09-03
US20190270755A1 (en) 2019-09-05
WO2017029602A2 (en) 2017-02-23
IL257265A (en) 2018-03-29
CN108137616A (zh) 2018-06-08
EP3334739A2 (en) 2018-06-20
US10683307B2 (en) 2020-06-16
PE20181143A1 (es) 2018-07-17
AU2019200226B2 (en) 2020-01-23
US10364254B2 (en) 2019-07-30
EA033314B1 (ru) 2019-09-30
CR20180111A (es) 2018-04-12
ZA201800722B (en) 2019-07-31
AU2016307969A1 (en) 2018-03-08
IL257265B (en) 2020-07-30
CN108137616B (zh) 2020-06-26
DOP2018000049A (es) 2018-03-30
MA42621A (fr) 2018-06-20
CA2995715A1 (en) 2017-02-23
KR20180038046A (ko) 2018-04-13
JP2018523675A (ja) 2018-08-23
AU2019200226A1 (en) 2019-01-31
JP6757402B2 (ja) 2020-09-16
AU2016307969C1 (en) 2019-09-05
CO2018002204A2 (es) 2018-06-20
WO2017029602A3 (en) 2017-04-13
TW201722965A (zh) 2017-07-01
AU2016307969B2 (en) 2019-02-14
UY36851A (es) 2017-03-31
EA201890412A1 (ru) 2018-08-31
US20190031680A1 (en) 2019-01-31
MX2018002033A (es) 2018-06-15
CL2018000403A1 (es) 2018-07-06

Similar Documents

Publication Publication Date Title
WO2016064082A3 (ko) 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
HK1248680A1 (zh) 包含吡嗪并[2，3-b][1，4]恶嗪-3-酮或相关环系的抗菌剂
WO2016011390A8 (en) Irak4 inhibiting agents
WO2017017631A3 (en) Antibacterial therapeutics and prophylactics
HK1247203A1 (zh) 取代的咪唑并[1，2-α]吡啶-2-基胺化合物及其药物组合物和使用方法
HK1206028A1 (en) Phenicol antibacterials
WO2015179441A3 (en) Macrocyclic broad spectrum antibiotics
MX2016009251A (es) Derivados de 7-oxo-1, 6-diazabiciclo [3.2.1] octano y su uso como agentes antibacterianos.
EP3102036A4 (en) 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
PH12019502509A1 (en) Compounds and methods for treating bacterial infections
WO2016100578A3 (en) Antimicrobial polymyxins for treatment of bacterial infections
WO2016125192A3 (en) Processes for the preparation of dolute-gravir
WO2014022382A3 (en) Antibacterial protein kinase inhibitors
MX2019011908A (es) Macrociclos de peptidos anti-bacterianos y uso de los mismos.
WO2018109042A3 (en) Antimicrobial peptides
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
EP3273797A4 (en) Composition inhibiting gram-positive, pathogenic bacteria
HK1202452A1 (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
WO2015114452A3 (en) Antibacterial combinations comprising polymyxin
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2017158616A8 (en) Carbapenem compounds
WO2015199418A3 (ko) 신규한 헤테로고리 화합물
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
WO2015001568A3 (en) Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.